Rare but important risks include pancreatitis, gallstones or gallbladder issues, and worsening of advanced diabetic eye disease in certain individuals
Cardiovascular benefits have been demonstrated in clinical trials for specific GLP-1 receptor agonists, with liraglutide, semaglutide, and dulaglutide showing reductions in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk
Neurogastroenterol Motil 2010;22:664-e203.ArticlePubMed 26
It's not recommended, but plenty of people do it Quit a GLP-1
Regardless, they will receive their medications outside of a standard pharmacy
He used alcohol to remove larger proteins present in the extracts to enrich the amount of active substance in the extracts (Hall